Abstract:Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths in the United States and worldwide. Receptor tyrosine kinase (RTK) signaling through Epidermal Growth Factor Receptor (EGFR) has been shown to play a key role in the development and progression of NSCLC. Two activating mutations within EGFR, L858R and del19, have been demonstrated to lead to oncogene addiction and have also been shown to confer sensitivity to targeted EGFR inhibitors (e.g. erlotinib and gefitinib). Earlier work has demonstrated a crucial role for the EGFR downstream effector c-Src in the upregulation of Vascular Endothelial Growth Factor (VEGF), a HIF-1\#945; regulated gene. We have identified a correlation between mutant EGFR and elevated HIF-1\#945; protein levels. Thus, we hypothesized that c-Src may be a critical downstream effector of mutant EGFR and may have a central role in the upregulation of HIF-1\#945; signaling by activated EGFR. NSCLC cell lines were treated with erlotinib to demonstrate a role for mutant EGFR in the upregulation of HIF-1\#945; and subsequently VEGF protein levels. HCC827 NSCLC cells, expressing the EGFR sensitizing mutant, had significantly reduced HIF-1\#945; protein levels and VEGF secretion when treated with the EGFR inhibitor, whereas, A549 cells, expressing the wild-type EGFR, were minimally effected by erlotinib treatment, compared their respective untreated controls. Furthermore, transient transfection with del19 EGFR led to increased VEGF promoter activity as demonstrated by a luciferase assay. These data demonstrate a central role for mutant EGFR signaling in the upregulation of HIF-1\#945; protein levels and VEGF secretion. Hence, signaling through mutant EGFR uncouples the normal regulation of HIF-1\#945; from hypoxia leading to aberrant expression of the angiogenic growth factor, VEGF. To identify critical signaling pathways potentially involved in the EGFR-induced up-regulation of HIF-1\#945;, multiple inhibitors were utilized. Inhibition of Mek did not affect HIF-1\#945; protein levels compared to controls, whereas inhibition of phosphotidylinositol-3-kinase (PI3K) led to a 50% reduction in HIF-1\#945; protein levels versus untreated cells. The Src family inhibitor PP2 led to a complete reduction of HIF-1\#945; protein, and similar results were seen with erlotinib. Moreover, erlotinib and PP2 led to a partial reduction of HIF-2\#945; protein levels. Collectively, our data demonstrate that NSCLC cells expressing activating mutations in EGFR have elevated HIF-1\#945; protein levels and that the c-Src signaling pathway may play a central role in the uncoupling of HIF-1\#945; signaling from hypoxia-induced regulation. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4216.

EGF Upregulates RFPL3 and Htert Via the MEK Signaling Pathway in Non‑small Cell Lung Cancer Cells.

Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells.

Ehf Enhances Malignancy By Modulating Akt And Mapk/Erk Signaling In Non-Small Cell Lung Cancer Cells

Overexpression of ELF3 Facilitates Cell Growth and Metastasis Through PI3K/Akt and ERK Signaling Pathways in Non-Small Cell Lung Cancer

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

Abstract 5868: Upregulation of HER3 and MET in non-small cell lung cancer cells resistant to EGFR tyrosine kinase inhibitor

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

HOTAIR Induces EGFR-TKIs Resistance in Non-Small Cell Lung Cancer Through Epithelial-Mesenchymal Transition.

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Abstract #4216: A Role for C-Src in EGFR-induced Upregulation of HIF-1\#945;

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth

Sensitivity of Non-Small Cell Lung Cancer to Erlotinib is Regulated by the Notch/Mir-223/Fbxw7 Pathway

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.

The EGFR Pathway is Involved in the Regulation of PD-L1 Expression Via the IL-6/JAK/STAT3 Signaling Pathway in EGFR-mutated Non-Small Cell Lung Cancer.

Preliminary Mechanisms of Regulating PD‑L1 Expression in Non‑small Cell Lung Cancer During the EMT Process.

Elevated RET Expression Enhances EGFR Activation and Mediates EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma.

Metastasis-associated PRL-3 Induces EGFR Activation and Addiction in Cancer Cells

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

EGF Induced CXCR4 Expression in NSCLC Cell Through PI-3K Signaling Pathway

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer